American Biogenetics acquires Stellar :
This article was originally published in Clinica
American Biogenetic Sciences has bought Stellar Bio Systems in a staged payment deal that could total around $1.4 million in stock and cash. According to ABS, the acquisition will bring it access to new distribution channels for ABS' Thrombus Precursor Protein (tpP) and Functional Intact Fibrinogen (FiF) diagnostic tests. It will also provide its own immunodiagnostic test menu and Antigen Free technology, to produce monoclonal antibodies unattainable by conventional means. ABS will make an initial payment of $700,000 in stock and $120,000 in cash with milestone payments over the next three years.
You may also be interested in...
Abbott reported almost 28% revenue growth in the fourth quarter led by the exploding demand for COVID-19 tests and continued success of its FreeStyle Libre continuous glucose monitor.
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.